Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

February 28, 2015

Conditions
Type 2 Diabetes
Interventions
DRUG

Dapagliflozin

Tablets, Oral, 10 mg, Once daily, Up to 52 weeks

DRUG

Placebo matching with Dapagliflozin

Tablets, Oral, 0 mg, Once daily, Up to 52 weeks

DRUG

Saxagliptin

Tablets, Oral, 5 mg, Once daily, Up to 52 weeks

DRUG

Metformin immediate release (IR)

Tablets, Oral, ≥ 1500 mg, Twice daily, Up to 52 weeks

Trial Locations (66)

20127

Local Institution, Aguascalientes

23454

Tidewater Integrated Medical Research, Virginia Beach

28204

Metrolina Internal Medicine, Charlotte

32765

Compass Research East, Llc, Oviedo

32804

Omega Research Consultants, Llc, Orlando

33012

Palm Springs Research Institute, Hialeah

33183

International Research Associates, Llc, Miami

34684

Palm Harbor Medical Associates, Palm Harbor

34741

Fpa Clinical Research, Kissimmee

35294

University Of Alabama At Birmingham, Birmingham

39159

Jackson Clinic, Rolling Fork

44670

Local Institution, Guadalajara

45116

Local Institution, Zapopan

45200

Local Institution, Zapopan

45246

Sterling Research Grp, Ltd., Cincinnati

47714

Clinical Research Advantage, Evansville

49015

Associated Internal Medicine Specialists, Battle Creek

60607

Cedar Crosse Research Center, Chicago

64060

Local Institution, Monterrey

64460

Local Institution, Monterrey

72205

Arkansas Clinical Research, Little Rock

77004

Endocrine Associates, Houston

78229

Sam Clinical Research Center, San Antonio

85018

Clinical Research Advantage, Inc., Phoenix

Elite Clinical Studies, Llc, Phoenix

85213

Clinical Research Advantage Inc/Desert Clinical Research Llc, Mesa

90023

Randall G. Shue, Do, Inc., Los Angeles

90057

National Research Institute, Los Angeles

90717

Torrance Clinical Research Institute Inc., Lomita

91325

Diabetes Medical Center Of California, Northridge

92083

Cassidy Medical Group/Clinical Research Advantage, Vista

100097

Local Institution, Ploieşti

119034

Local Institution, Moscow

150062

Local Institution, Yaroslaval

194044

Local Institution, Saint Petersburg

194156

Local Institution, Saint Petersburg

195112

Local Institution, Saint Petersburg

195257

Local Institution, Saint Petersburg

197022

Local Institution, Saint Petersburg

197136

Local Institution, Saint Petersburg

200349

Local Institution, Craiova

305035

Local Institution, Kursk

800098

Local Institution, Galati

900591

Local Institution, Constanța

08611

Premier Research, Trenton

550 01

Local Institution, Broumov

530 02

Local Institution, Pardubice

100 00

Local Institution, Prague

149 00

Local Institution, Prague

261 95

Local Institution, Pribram V

15-435

Local Institution, Bialystok

30-015

Local Institution, Krakow

41-709

Local Institution, Ruda Śląska

00-465

Local Institution, Warsaw

01-868

Local Institution, Warsaw

03-003

Local Institution, Warsaw

44-240

Local Institution, Żory

00909

Clinical Research Puerto Rico, San Juan

070208

Local Institution, Bucharest

010825

Local Institution, Bucharest

PO3 6LY

Local Institution, Portsmouth

PO30 5TG

Local Institution, Newport

L7 8XP

Local Institution, Liverpool

SN15 1HP

Local Institution, Chippenham

SG19 3JR

Local Institution, Bedfordshire

W6 7HY

Local Institution, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY